P1048: PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA: RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES

類似資料

• Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers
  著者:: Nishit B. Modi, 等
  出版事項: (2024-11-01)
• P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS
  著者:: Andrew Kuykendall, 等
  出版事項: (2023-08-01)
• P1028: PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA
  著者:: A. Kuykendall, 等
  出版事項: (2022-06-01)
• Splenectomy normalizes hematocrit in murine polycythemia vera.
  著者:: Jan-Rung Mo, 等
  出版事項: (2009-09-01)
• Introducing heat-not-burn tobacco improves hematocrit and cigarette smoking-related symptoms in patients with smokers' polycythemia and polycythemia vera.
  著者:: Kazuhide Iizuka, 等
  出版事項: (2025-01-01)